Press Releases Ypsomed Group

Burgdorf – Following the successful launch of its own insulin pump, the mylife YpsoPump, Ypsomed pursues its continued growth and invests in establishing new subsidiaries throughout Europe. At the same time, the mylife YpsoPump is being launched in further European countries.

Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval.

Press Releases Ypsomed Group

Burgdorf – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen platform, facilitates subcutaneous administration with its patient friendly design.

Press Releases Ypsomed Group

Burgdorf – On 26th September 2017, groundbreaking took place for Ypsomed’s new production facility in the Industrial Park of Schwerin, Germany. Ypsomed is to invest over EUR 100 million in the new production site. Production will commence during the first half of 2019. Ypsomed plans to create roughly 150 jobs in the region over the next five years.

Press Releases Ypsomed Group

Burgdorf – Ypsomed has been the exclusive distributor for the mylife™ OmniPod® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife™ YpsoPod® insulin pump in the mid-term.